Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:CRONNASDAQ:EOLSNASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.46+2.1%$2.31$1.29▼$7.85$160.18M1.241.80 million shs870,047 shsCRONCronos Group$1.77$1.86$1.60▼$3.14$682.17M1.021.46 million shs2.25 million shsEOLSEvolus$10.79+6.7%$12.62$8.67▼$17.82$686.10M0.97660,105 shs1.05 million shsPHVSPharvaris$14.00+2.0%$15.13$11.51▼$25.50$732.06M-2.8469,485 shs10,082 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+2.10%+5.80%-41.60%-65.24%-68.16%CRONCronos Group0.00%+5.36%-4.32%-11.06%-26.86%EOLSEvolus+6.73%+14.67%-18.75%+2.66%-7.30%PHVSPharvaris+2.04%+17.65%-12.28%-23.75%-33.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.5693 of 5 stars3.53.00.00.02.81.70.6CRONCronos Group1.5571 of 5 stars2.05.00.00.02.00.01.3EOLSEvolus3.5077 of 5 stars3.51.00.03.51.72.50.6PHVSPharvaris1.4031 of 5 stars3.51.00.00.02.40.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.671,178.54% UpsideCRONCronos Group 0.00N/A$3.5097.74% UpsideEOLSEvolus 3.00Buy$23.75120.11% UpsidePHVSPharvaris 3.00Buy$40.50189.29% UpsideCurrent Analyst Ratings BreakdownLatest ANNX, CRON, PHVS, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.003/5/2025EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/14/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.001/31/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $55.001/27/2025EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $22.001/22/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ACRONCronos Group$117.62M5.80N/AN/A$2.87 per share0.62EOLSEvolus$266.27M2.58N/AN/A($0.36) per share-29.97PHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)CRONCronos Group-$73.96M$0.10N/A59.001.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)EOLSEvolus-$61.69M-$0.81N/AN/AN/A-22.33%-847.60%-22.15%5/6/2025 (Estimated)PHVSPharvaris-$109.18M-$2.68N/AN/AN/AN/A-38.52%-36.69%5/14/2025 (Estimated)Latest ANNX, CRON, PHVS, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/APHVSPharvaris-$0.80N/AN/AN/AN/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A5/6/2025Q1 2025EOLSEvolus-$0.04N/AN/AN/A$73.06 millionN/A4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18CRONCronos GroupN/A24.2423.05EOLSEvolus20.582.472.23PHVSPharvarisN/A19.0819.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ACRONCronos Group8.71%EOLSEvolus90.69%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%CRONCronos Group6.90%EOLSEvolus6.10%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableEOLSEvolus17063.59 million59.46 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableANNX, CRON, PHVS, and EOLS HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Stock Price Up 7.8% - Still a Buy?April 17 at 1:46 PM | marketbeat.comFmr LLC Has $103.43 Million Holdings in Pharvaris (NASDAQ:PHVS)April 16 at 3:55 AM | marketbeat.comPharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial PositionApril 14, 2025 | tipranks.comQ1 Earnings Estimate for Pharvaris Issued By Leerink PartnrsApril 12, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q1 Earnings (NASDAQ:PHVS)April 12, 2025 | marketbeat.comWedbush Brokers Decrease Earnings Estimates for PharvarisApril 12, 2025 | americanbankingnews.comWhat is Wedbush's Estimate for Pharvaris FY2029 Earnings?April 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Hits New 12-Month Low - Here's What HappenedApril 11, 2025 | marketbeat.comWhat is Wedbush's Forecast for Pharvaris FY2029 Earnings?April 11, 2025 | americanbankingnews.comPharvaris’s Strategic Advancements and Strong Financial Position Drive Buy RatingApril 10, 2025 | tipranks.comPharvaris (NASDAQ:PHVS) Stock Price Down 8.4% - Here's What HappenedApril 9, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSApril 9, 2025 | marketbeat.comPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last yearApril 8, 2025 | markets.businessinsider.comPharvaris Reports 2024 Financial Results and Business ProgressApril 8, 2025 | tipranks.comPharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market ExpansionApril 7, 2025 | tipranks.comPharvaris Reports 2024 Financial Results and Advances HAE Treatment StudiesApril 7, 2025 | tipranks.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | gurufocus.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Sets New 12-Month Low - Time to Sell?April 5, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - What's Next?April 4, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 4.3% - What's Next?April 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingMicron Stock Will Retest All-Time Highs This YearBy Thomas Hughes | March 21, 2025View Micron Stock Will Retest All-Time Highs This YearMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesANNX, CRON, PHVS, and EOLS Company DescriptionsAnnexon NASDAQ:ANNX$1.46 +0.03 (+2.10%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.51 +0.05 (+3.42%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Cronos Group NASDAQ:CRON$1.77 0.00 (0.00%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.78 +0.01 (+0.85%) As of 04/17/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Evolus NASDAQ:EOLS$10.79 +0.68 (+6.73%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$10.78 0.00 (-0.05%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Pharvaris NASDAQ:PHVS$14.00 +0.28 (+2.04%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$14.00 0.00 (0.00%) As of 04/17/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
